Clinical trials: Risperidone
Schizophrenia
Study Evaluating Vabicaserin in Subjects With Schizophrenia
The primary purpose of this protocol is to establish the efficacy, safety, and tolerability of vabicaserin (SCA-136) using a once a day capsule in subjects with acute exacerbations of schizophrenia.
- Trial name
- NCT00563706
- Testing
- vabicaserin, risperidone
- Where
- 33 sites in United States, Canada
- Volunteers
- 199 people
- Sponsor
- Pfizer
Healthy
Bioequivalence Study of Risperidone 1.0 mg Tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fasting Conditions
Objective: To assess the bioequivalence of Risperidone 1.0 mg tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg tablets of Janssen Pharmaceutical Products, LP, USA, in healthy human adult…
- Trial name
- NCT00939497
- Testing
- Risperidone
- Where
- India
- Sponsor
- Torrent Pharmaceuticals Limited
Psychoses
DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics
The purpose of this study is to assess patients treated with the antipsychotics aripiprazole (Abilify®), olanzapine (Zyprexa®), quetiapine (Seroquel®), risperidone (Risperdal®), or ziprasidone (Geodon®) and to identify genetic…
- Trial name
- DIMS (NCT00752960)
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Genomas, Inc
Schizophrenia, Bipolar Disorder
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events…
- Conditions
- Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
- Trial name
- NCT01050582
- Testing
- Risperidone, Other atypical antipsychotic drugs
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 244 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Schizophrenia
Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia
This is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of intramuscular (IM) injections of Risperidone ISM® (75 or 100 mg) or placebo, in patients with acute…
- Trial name
- PRISMA-3 (NCT03160521)
- Testing
- Risperidone ISM 75 mg, Risperidone ISM 100 mg
- Where
- 31 sites in United States, Ukraine
- Volunteers
- 438 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Schizophrenia
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period.
- Trial name
- NCT01175135
- Testing
- PF-02545920, Risperidone
- Where
- 46 sites in United States, Germany and 1 more
- Volunteers
- 259 people
- Sponsor
- Pfizer
Schizophrenia
An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia
The purpose of this study is to evaluate the long-term treatment efficacy, and safety of risperidone long-acting injection in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- NCT01894984
- Testing
- Risperidone, Oral atypical anti-psychotic
- Volunteers
- 640 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia, Schizoaffective Disorder
A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder
The purpose of the study is to compare the time to relapse in patients with schizophrenia and schizoaffective disorders receiving risperidone or haloperidol (antipsychotic medications) for at least 1 year.
- Trial name
- NCT00253110
- Testing
- risperidone, haloperidol
- Volunteers
- 396 people
- Sponsor
- Janssen, LP
Schizophrenia
Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy
Evaluate the safety and tolerability of multiple subcutaneous injections of various dosages of risperidone with clinically stable schizophrenia
- Trial name
- NCT01677377
- Testing
- Risperidone, RBP-7000
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Indivior Inc.
Schizophrenia
A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia
The purpose of this study is a noninferiority comparison of the orthostatic tolerability of a dose of 12 mg extended-release (ER) OROS paliperidone with the current recommended initial titration dose (2 mg) of immediate-release…
- Trial name
- NCT00791232
- Testing
- extended-release (ER) OROS paliperidone
- Volunteers
- 113 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizo-affective Disorder
Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
The study will be a 6-month, open-label, multiple center study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of Risperidone…
- Trial name
- NCT02658357
- Testing
- Risperidone Implant
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Braeburn Pharmaceuticals
Depressive Disorder, Depressive Disorder, Major
A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression
The purpose of this study is to evaluate the effectiveness and safety of risperidone to augment SSRI therapy in patients with treatment-resistant depression and to demonstrate the long-term maintenance effect of risperidone as…
- Conditions
- Depressive Disorder, Depressive Disorder, Major, Depression
- Trial name
- NCT00044681
- Testing
- risperidone
- Volunteers
- 258 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to assess the time for patients to relapse when switched from an oral antipsychotic to one of two doses of long-acting risperidone injection (shots).
- Trial name
- NCT00297388
- Testing
- Risperidone, long-acting injectable
- Volunteers
- 40 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Psychotic Disorders
A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
The purpose of the study is to show that risperidone (an antipsychotic medication) combined with lorazepam (an anti-anxiety medication) is more effective than conventional therapy administered by intramuscular injection for…
- Conditions
- Schizophrenia, Psychotic Disorders, Emergency Treatment
- Trial name
- NCT00249171
- Testing
- risperidone
- Volunteers
- 226 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Healthy
Bioequivalence Study of Risperidone 1 mg Tablets of Torrent Pharmaceuticals Limited, India and Risperdal® (Risperidone) 1 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fed Conditions
Objective: To assess the bioequivalence of Risperidone 1.0 mg tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg tablets of Janssen Pharmaceutical Products, LP, USA, in healthy human adult…
- Trial name
- NCT00939926
- Testing
- Risperidone
- Where
- India
- Sponsor
- Torrent Pharmaceuticals Limited
Schizophrenia
SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia
This study was designed to compare the [123]I-CNS 1261 binding to NMDA receptor between healthy volunteers and different subgroups of schizophrenic patients.
- Trial name
- NCT00364429
- Testing
- [123]I-CNS 1261, Lorazepam, Risperidone
- Where
- Spain
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone
The purpose of this study is to evaluate the maintenance of clinical effect of a rapidly-dissolving tablet form of risperidone (an antipsychotic medication) in adult schizophrenia patients switched from their previous equivalent…
- Trial name
- NCT00246272
- Testing
- risperidone
- Volunteers
- 82 people
- Sponsor
- Janssen-Ortho Inc., Canada
Bipolar Disorder
A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders
The purpose of this study is to assess the potential pharmacokinetic (absorption, distribution and excretion of the drug by the body) interaction between, and the safety of, topiramate and risperidone administered in combination…
- Trial name
- NCT00986336
- Testing
- topiramate, risperidone
- Volunteers
- 56 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to assess the maintenance of antipsychotic efficacy and safety of risperidone long-acting injectable (RLAI) in patients with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- NCT01888107
- Testing
- Risperidone Long-acting Injectable (LAI) 25 mg, Risperidone LAI 37.5 mg, Risperidone LAI 50 mg
- Volunteers
- 347 people
- Sponsor
- Janssen-Cilag S.p.A.
Bipolar Disorders, Manic Disorder
A Study of the Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol
The purpose of the study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) compared with placebo after 3 weeks of treatment in patients with bipolar disorder who are experiencing manic…
- Trial name
- NCT00253162
- Testing
- risperidone
- Volunteers
- 439 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.